Phase 2 N=24 Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Chronic Rhinosinusitis (Diagnosis) · Nasal Polyps · Eosinophilia
Primary: Change in Nasal Polyp Score — .9; .3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=134 Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Melanoma
Primary: Non-progression Rate After Six Cycles — 13; 18; 52; 47 Participants
Phase 2 N=20 Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
Subarachnoid Hemorrhage, Aneurysmal · Delayed Cerebral Ischemia · Vasospasm, Cerebral
Primary: Participants With Adverse Events — 2; 0; 0; 0 Participants
Phase 2 N=2 Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: This Trial Will Use DOXIL and Abraxane as First or Second Line Chemotherapy in Patients With a Diagnosis of Metastatic Breast Cancer (MBC).
Phase 2 N=10 A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Critical Limb Ischemia · Vascular Diseases · Peripheral Arterial Disease
Primary: Number of Participants With Adverse Events (AEs) Suspected to be Related to Injections of AMG0001 — 1; 1; 1; 1 Participants
Phase 2 N=40 Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Colon Cancer · Colorectal Cancer · Colorectal Carcinoma
Primary: Phase I - Recommended Phase II Dose (RP2D) — 560 mg
Phase 2 N=45 Effects of Random Nicotine Delivery on Smoking Cessation
Smoking Cessation · Cigarette Smoking · Smoking (Tobacco) Addiction
Primary: Change in Number of Cigarettes Smoked Per Day (CPD) — -10.3; -9.0; -7.6 cigarettes per day — p=.55
Phase 2 N=18 Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Pancreatic Cancer
Primary: Response Rate as Measured Per RECIST 1.1 Criteria — 12; 2 Participants
Phase 2 N=50 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Acoustic Schwannoma · Adult Anaplastic Meningioma · Adult Ependymoma
Primary: Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months — 93; 85; 51; 73 percentage of patients
Phase 2 N=12 Safety and Efficacy of LCI699 in Cushing's Disease Patients
Cushings Disease · Cushing Disease
Primary: Percentage of Responders to LCI699 Based on the Change in Mean Urinary Free Cortisol (UFC) From Baseline to Week 10 — 100.0 Percentage of participants
Phase 2 N=120 Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15
Acute Pain
Primary: Summed Pain Intensity Difference Over the First Six Hours — -420.2; -1101.0; -1771.7; -1463.5 units on a scale — p=<0.0001
Phase 2 N=80 Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands
Platysmal Bands
Primary: Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo — 3; 36 Participants
Phase 2 N=41 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) Myelofibrosis · Postessential Thrombocythemia (Post-ET) Myelofibrosis
Primary: Transfusion Independence Response by Week 24 — 34.1 percentage of subjects
Phase 2 N=11 Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Melanoma · Malignant Melanoma · Stage IIIA Melanoma
Primary: Overall Response Rate, Defined as the Percentage of Patients With a Confirmed Clinical Response (CR) or Partial Response (PR) — 3 Participants
Phase 2 N=36 Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
High Grade Upper Tract Urothelial Carcinoma
Primary: Complete Pathologic Response Rate — 0.103; 0.167 proportion of participants